Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353383 | 1.00 | L3MBTL1 (0.64) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL4342209 | 0.97 | L3MBTL1 (0.70) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL4342213 | 0.97 | L3MBTL1 (0.70) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL4352810 | 0.89 | L3MBTL1 (0.58) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL4352808 | 0.89 | L3MBTL1 (0.58) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL4341252 | 0.88 | L3MBTL1 (0.61) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL4341256 | 0.88 | L3MBTL1 (0.61) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL4350473 | 0.87 | L3MBTL1 (0.49) | L3MBTL1SMN1; SMN2ALDH1A1POLBKMT2A | |
| SCHEMBL4350478 | 0.87 | L3MBTL1 (0.49) | L3MBTL1SMN1; SMN2ALDH1A1POLBKMT2A | |
| SCHEMBL4355722 | 0.85 | L3MBTL1 (0.67) | L3MBTL1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569573-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1848697-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-7250421-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060223834-A1 | Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006083553-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060172973-A1 | Nucleobase substituted with a 2-hydroxy-4-oxobut-2-enoic acid or ester or a 1-hydroxy-3-oxopropenephosphonic acid or ester, e.g., Methyl 4-(1,3-dibenzyl-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)-2-hydroxy-4-oxobut-2-enoate | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223834-A1 | Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae | EIF2AK2, DCK, RNGTT | L3MBTL1 2212/4885CA12 4836/4885CA1 4857/4885 |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | DCK, DTYMK, DUT | L3MBTL1 2208/4885CA12 4840/4885CA1 4730/4885 |
| US-20060172973-A1 | Nucleobase substituted with a 2-hydroxy-4-oxobut-2-enoic acid or ester or a 1-hydroxy-3-oxopropenephosphonic acid or ester, e.g., Methyl 4-(1,3-dibenzyl-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)-2-hydroxy-4-oxobut-2-enoate | DUT, DERA, DCK | L3MBTL1 1052/4885CA12 4812/4885CA1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.